PDE3B
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B
As of the edition of 20 October 2026, PDE3B (cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B, UniProt Q13370) has 8 drugs tested at it and 6 companies on the list, 1 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q13370
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 4
- Disease areas
- Heart and blood vessels; Lungs and airways; Nervous system; Nutrition and metabolism; Urinary and reproductive; Blood and lymph; Immune system; Pregnancy and women's health
- Registered trials of its drugs
- 177
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 6 |
| Active | 1 |
| Went quiet | 1 |
| Total | 8 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Theophylline anhydrous | Marketed | Phase 4 | none listed |
| Levosimendan | Marketed | Phase 4 | none listed |
| Ensifentrine | Marketed | Phase 3 | Ends 2031 |
| Anagrelide | Marketed | Phase 4 | none listed |
| Enoximone | Marketed | Phase 4 | none listed |
| K-134 | Went quiet | Phase 2 | none listed |
| TNX-103 | Active | Phase 3 | none listed |
| Theophylline glycinate | Marketed | No phase stated | none listed |
8 of 8 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 1 |
| Engaged | 1 |
| Undetermined | 3 |
| Total on the list | 6 |
The other 4 companies at PDE3B
In the product6 companies in all; 4 are not named here, and no score is.
See the 6 companies at PDE3B, ranked, with the facts behind eachRequest access. Nothing is shown until you do.